Journal profile · Biochemistry & Molecular Biology
Epigenetics
ISSN 1559-2294 · eISSN 1559-2308 · Landes Bioscience · UNITED STATES · Quarterly · Founded 2006
Epigenetics: CAS Zone 3 · Biology (2025 upgraded edition); impact factor 3.69; JCR Q2 (journal website); fully open access; APC about USD 3,300; median 126 days to acceptance (93 articles, last 24 months); acceptance rate 29% (journal website); 70 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Epigenetics is published by Landes Bioscience and is in Zone 3 of Biology in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Epigenetics and DNA Methylation, RNA modifications and cancer and Cancer-related gene regulation, together about 52.4% of its articles. Its main subfields are Molecular Biology. (generated from OpenAlex topic counts and CAS ranking data)
Epigenetics publishes international research into heritable changes in gene expression caused by mechanisms other than the modification of the DNA sequence. Epigenetics, as a leading journal in the field, provides a platform for presenting and discussing cutting-edge epigentic research. The journal considers submissions that investigate how environmental factors via epigenetic mechanisms and how epigenetic mechanisms themselves can influence gene expression and diverse biological functions to exert their role in disease, aging, and developmental processes. This includes everything from research into epigenetic mechanisms (e.g., nucleosome positioning, DNA methylation, histone covalent modifications, non-coding RNAs, imprinting to chromatin remodelling complexes, and epigenetic RNA modifications-epitranscriptomics), and the role of epigenetics in life, health, and disease, including epigenetic therapy and diagnostics. Epigenetics considers the following manuscripts for acceptance: Research papers Technical papers Brief communications Reviews Point of views Commentaries Editorials and Letters to the editor The journal operates a single anonymized peer review policy. *Please note that Epigenetics converted to a fully open access journal from Volume 18 (2023). Previous volumes will continue to provide access through a Pay-to-Read model. From 2023, the Print ISSN will not be in active use as this journal is no longer published in print.
From the journal's Aims & Scope
Research area (LetPub): Biochemistry & Molecular Biology
Editor-in-chief Manel EstellerPublisher website
Main research topics OpenAlex counts of recent articles; shares are approximate
- Epigenetics and DNA MethylationBiochemistry, Genetics and Molecular Biology35.4%
- RNA modifications and cancerBiochemistry, Genetics and Molecular Biology8.7%
- Cancer-related gene regulationBiochemistry, Genetics and Molecular Biology8.2%
- Genomics and Chromatin DynamicsBiochemistry, Genetics and Molecular Biology6.8%
- Genetic Syndromes and ImprintingBiochemistry, Genetics and Molecular Biology6.3%
- Birth, Development, and HealthMedicine5.1%
- Cancer-related molecular mechanisms researchBiochemistry, Genetics and Molecular Biology4%
- Genetics and Neurodevelopmental DisordersBiochemistry, Genetics and Molecular Biology3%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Biology Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Biology | Zone 3 |
| Minor | Biochemistry & Molecular Biology | Zone 3 |
| Minor | Genetics & Heredity | Zone 3 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Biology Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Biology | Zone 2 |
| Minor | Biochemistry & Molecular Biology | Zone 2 |
| Minor | Genetics & Heredity | Zone 2 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Biology Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Biology | Zone 3 |
| Minor | Biochemistry & Molecular Biology | Zone 3 |
| Minor | Genetics & Heredity | Zone 3 |
Top journal: noReview journal: no
JCR / CiteScore quartiles on the journal's website
- JCR Q2 · best quartile · 2025
- CiteScore Q2 · 2025
Publisher-reported: JCR figures are Clarivate's and CiteScore figures Scopus's to confirm; both are a different system from the CAS zones.Publisher website
Database indexing
SCIEScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
Web of ScienceMEDLINEPMCEmbasePublisher website
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 3.69LetPub ·
- Impact factor (publisher) 2025
- 3.7Publisher website ·
- 5-year impact factor (publisher) 2025
- 3.7Publisher website ·
- CiteScore 2026-06
- 7.4LetPub ·
- CiteScore (publisher) 2025
- 7.4Publisher website ·
- SJR 2026-06
- 1.05LetPub ·
- SJR (publisher) 2025
- 1.05Publisher website ·
- SNIP 2026-06
- 0.71LetPub ·
- SNIP (publisher) 2025
- 0.71Publisher website ·
- h-index
- 77LetPub ·
- h-index
- 138OpenAlex ·
- i10-index
- 1,693OpenAlex ·
- 2-year mean citedness
- 4.26OpenAlex ·
- Self-citation rate
- 2.7%LetPub ·
- Share of gold OA articles
- 100%LetPub ·
Volume
- Articles per year
- 66LetPub ·
- Articles per year (publisher)
- 2,023Publisher website ·
- Downloads per year (publisher)
- 775,000Publisher website ·
Articles by year OpenAlex count · 2,243 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 42 | 42 | 15 |
| 2025 | 70 | 70 | 280 |
| 2024 | 83 | 83 | 536 |
| 2023 | 111 | 111 | 1,602 |
| 2022 | 97 | 97 | 1,375 |
| 2021 | 80 | 80 | 1,776 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
126 daysMedian, submission to acceptance · P25–P75 93 days – 171 days
- Acceptance to online
- median 13 days (93 articles)
- Submission to online
- median 143 days
- Sample
- 93 articles with submission and acceptance dates (129 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- 3–8 weeksLetPub ·
- Acceptance rate (publisher)
- 29%Publisher website ·
- Submission to first decision
- 3 daysPublisher website ·
- First decision after review
- 51 daysPublisher website ·
- Acceptance to publication
- 17 daysPublisher website ·
- Submission to publication (journal-reported)
- about 10 weeksDOAJ ·
- Peer review
- Single anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | AUD 4,595 / EUR 3,170 / GBP 2,640 / USD 3,300 | Yes | CC BY, CC BY-NC | |
| Publisher website | USD 3,940 / GBP 2,920 / EUR 3,505 / AUD 5,485 | — | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare1 items from the author guidelines
- Abstract
- ≤ 350 words
Article types accepted7
- brief reportThis Journal accepts the following types of article: Research Article, Rapid Communication, Meeting Report, Review, Editorial, Letter to the Editor, and Brief R…Length not stated
- editorialThis Journal accepts the following types of article: Research Article, Rapid Communication, Meeting Report, Review, Editorial, Letter to the Editor, and Brief R…Length not stated
- letter to the editorThis Journal accepts the following types of article: Research Article, Rapid Communication, Meeting Report, Review, Editorial, Letter to the Editor, and Brief R…Length not stated
- meeting reportThis Journal accepts the following types of article: Research Article, Rapid Communication, Meeting Report, Review, Editorial, Letter to the Editor, and Brief R…Length not stated
- rapid communicationThis Journal accepts the following types of article: Research Article, Rapid Communication, Meeting Report, Review, Editorial, Letter to the Editor, and Brief R…Length not stated
- research articleThis Journal accepts the following types of article: Research Article, Rapid Communication, Meeting Report, Review, Editorial, Letter to the Editor, and Brief R…Length not stated
- reviewThis Journal accepts the following types of article: Research Article, Rapid Communication, Meeting Report, Review, Editorial, Letter to the Editor, and Brief R…Length not stated
Policy excerpts from the journal's websiteConflicts of interest, Data availability, License & copyright, Open access, Peer review
- Conflicts of interest Disclosure Statement
Please include a disclosure statement, using the subheading “Disclosure of interest.” If you have no interests to declare, please state this (suggested wording: The authors report no conflict of interest). For all NIH/Wellcome-funded papers, the grant number(s) must be included in the declaration of interest statement. Read more on declaring conflicts of interest.
Source ↗Publisher website ·- Data availability Data Sharing Policy
Data sharing policy Model summary
This journal applies the Taylor & Francis publicly available data sharing policy. Authors are required to make the data and materials supporting the results or analyses presented in their paper freely available. Authors may, however, choose to apply a licence that limits re-use. If the data cannot be made open, we recommend it is still preserved in a FAIR-compliant repository with appropriate acce…
Source ↗Publisher website ·- License & copyright Copyright Options
Copyright allows you to protect your original material, and stop others from using your work without your permission. Taylor & Francis offers a number of different license and reuse options, including Creative Commons licenses when publishing open access. Read more on publishing agreements.
Source ↗Publisher website ·- Open access Open access
English only Model summary
Overview Open journals Open Select Dove Medical Press F1000Research
Source ↗Publisher website ·- Peer review Peer Review and Ethics
Single anonymous peer review Model summary
Taylor & Francis is committed to peer-review integrity and upholding the highest standards of review. Once your paper has been assessed for suitability by the editor, it will then be single anonymous peer-reviewed by independent expert referees. If you have shared an earlier version of your Original Manuscript on a preprint server, please be aware that anonymity cannot be guaranteed. Further infor…
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Landes Bioscience
- Country or region
- UNITED STATES
- Language
- English
- Frequency
- Quarterly
- Founded
- 2006
- ISSN
- 1559-2294
- Electronic ISSN
- 1559-2308
- Latest issue on the website
- Volume 21, Issue 1 (2026)
- Official links
- Journal homepage ↗DOAJ
- Submission system ↗Publisher website
- Author guidelines ↗DOAJ
- Aims & Scope ↗DOAJ
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗DOAJ
- Editorial board ↗DOAJ
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about Epigenetics
What CAS zone is Epigenetics in?
In the 2025 upgraded edition of the CAS Journal Ranking, Epigenetics is in Zone 3 of Biology, and in Zone 3 of the minor category Biochemistry & Molecular Biology / Genetics & Heredity. In the 2026 Xinrui edition it is in Zone 2 of Biology. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Epigenetics?
The latest impact factor listed by LetPub is 3.69; CiteScore 7.4, h-index 138.
How long does peer review take at Epigenetics?
Based on the dates recorded on 93 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 126 days (interquartile range 93–171 days); authors report an average review time of 3–8 weeks; the journal's website gives an acceptance rate of 29%. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What JCR quartile is Epigenetics in?
The journal's website gives JCR Q2 (best quartile). JCR quartiles are Clarivate's to confirm and a different system from the CAS zones; in the CAS ranking the journal is in Zone 3 of Biology.
Which databases index Epigenetics?
According to LetPub and DOAJ records, Epigenetics is indexed in SCIE, Scopus and DOAJ. The journal's website also lists Web of Science, MEDLINE, PMC and Embase; that list has not been checked against each database.
Is Epigenetics open access, and what is the APC?
Epigenetics is a fully open-access journal. APC about USD 3,300.
Sources and updates
The facts on this page come from LetPub, Publisher website, DOAJ, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .